The article suggests that analysts are focusing on key metrics beyond the usual revenue and EPS for Ionis Pharmaceuticals' Q4 2024 performance. This indicates a deeper analysis which could affect investor sentiment. However, without specific positive or negative insights, the short-term impact on the stock price remains neutral.